Unique ID issued by UMIN | UMIN000015565 |
---|---|
Receipt number | R000018086 |
Scientific Title | Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer |
Date of disclosure of the study information | 2014/10/30 |
Last modified on | 2014/10/30 12:32:40 |
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer
Japan |
Refractory small-cell lung cancer
Pneumology |
Malignancy
NO
To investigate the efficacy and safety of nab-paclitaxel in combination with carboplatin in refractory small-cell lung cancer
Safety,Efficacy
Phase II
Response rate (RR)
Disease control rate (DCR), Progression free survival (PFS), Overall survival (OS), and Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Nab-paclitaxel at the dose of 100mg/m2 (day 1, 8, 15) and carboplatin at the dose of area under curve 5 (day 1) are administered every 3 weeks. Treatment can be continued unless PD or toxicity that is not tolerable is found.
20 | years-old | <= |
75 | years-old | > |
Male and Female
1) Patients with histlogically or cytologically confirmed small cell lung cancer
2) Patients are difficult to treat with adapted drugs to the small cell lung cancer. (patients completed or not acceptable the standard chemotherapy)
3) 20<=, <75 years old
4) Without active cancer other than NSCLC
5) At least one measurable lesion
6) With adequate organ function
neutrophil count => 1,500/mm^3
platelet => 100,000/mm^3
hemoglobin => 9.0g/dL
AST/ALT < 2.5 times less than ULN
T.Bil <= 1.5mg/dL
serum creatinine <= 1.5mg/dL
ECG: without clinically problematic abnormalities
Peripheral neuropathy <= Grade 1
7) Life expectancy of at least 3 months
8) ECOG performance status 0 or 2
9) With written informed consent
1) Symptomatic brain metastasis
2) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy
3) With active double cancer or multicentric cancer
4) Treated with radiotherapy within the past four weeks.
5) With clinically important complications.
6) With pleural effusion or pericardial effusion accumulates which need drainage
7) With the history of hypersensitivity for nab-paclitaxel, CBDCA
8) Main organs had a serious medical risk factor, and the physicians judged treatment not to be safe.
9) Physician concludes that the patient's participation in this trial is inappropriate
22
1st name | |
Middle name | |
Last name | Yoshiki Ishii |
Dokkyo Medical University
Department of Pulmonary Medicine and Clinical Immunology
880 Kitakobayashi, Mibu, Tochigi, Japan
0282-87-2151
ishiiysk@dokkyomed.ac.jp
1st name | |
Middle name | |
Last name | Ryo Arai |
Dokkyo Medical University
Department of Pulmonary Medicine and Clinical Immunology
880 Kitakobayashi, Mibu, Tochigi, Japan
0282-87-2151
r-arai@dokkyomed.ac.jp
Dokkyo Medical University
Dokkyo Medical University
Self funding
Tochigi-kitakan Thoracic Oncology Research Organization (TOTORO)
NO
2014 | Year | 10 | Month | 30 | Day |
Unpublished
Open public recruiting
2014 | Year | 09 | Month | 03 | Day |
2014 | Year | 10 | Month | 30 | Day |
2014 | Year | 10 | Month | 30 | Day |
2014 | Year | 10 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018086